TVTX Latest Press Releases

-- November 3, 2026 --

Travere Therapeutics to Participate at Upcoming Investor Conferences Business Wire 4:30 PM

-- November 2, 2026 --

Travere Therapeutics Reports Third Quarter 2026 Financial Results Business Wire 4:01 PM

-- October 26, 2026 --

Travere Therapeutics to Report Third Quarter 2026 Financial Results Business Wire 4:30 PM

-- October 23, 2026 --

Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy Business Wire 7:20 PM

-- October 12, 2026 --

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:00 PM

-- October 2, 2026 --

Travere to Present New Data Supporting FILSPARI (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026 Business Wire 10:00 AM

-- September 30, 2026 --

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm PRNewswire 9:58 AM

-- September 23, 2026 --

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI (sparsentan) in Focal Segmental Glomerulosclerosis Business Wire 7:00 AM

-- September 21, 2026 --

Travere Therapeutics Announces Planned Chief Executive Officer Transition Business Wire 4:05 PM

-- September 17, 2026 --

Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum Business Wire 4:30 PM

-- September 11, 2026 --

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:00 PM

-- August 12, 2026 --

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:00 PM

-- August 5, 2026 --

Travere Therapeutics to Participate at Upcoming Investor Conferences Business Wire 4:30 PM

-- August 4, 2026 --

Travere Therapeutics Reports Second Quarter 2026 Financial Results Business Wire 4:01 PM

-- July 28, 2026 --

Travere Therapeutics to Report Second Quarter 2026 Financial Results Business Wire 4:30 PM

-- July 27, 2026 --

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm PRNewswire 8:50 AM

-- July 16, 2026 --

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm Globe Newswire 9:43 PM

-- July 10, 2026 --

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:00 PM

-- June 16, 2026 --

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027 Business Wire 4:30 PM

-- June 11, 2026 --

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:00 PM

Market Data Delayed 15 Minutes